Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Large Growth in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 103,800 shares, a growth of 95.5% from the January 15th total of 53,100 shares. Currently, 3.4% of the company’s shares are short sold. Based on an average daily trading volume, of 2,240,000 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, Chardan Capital restated a “buy” rating and set a $10.00 target price on shares of Senti Biosciences in a report on Monday, December 2nd.

Institutional Trading of Senti Biosciences

An institutional investor recently bought a new position in Senti Biosciences stock. Renaissance Technologies LLC bought a new stake in Senti Biosciences, Inc. (NASDAQ:SNTI) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 51,600 shares of the company’s stock, valued at approximately $181,000. Renaissance Technologies LLC owned 1.07% of Senti Biosciences at the end of the most recent quarter. 25.73% of the stock is currently owned by hedge funds and other institutional investors.

Senti Biosciences Stock Down 1.6 %

NASDAQ SNTI traded down $0.07 during trading on Thursday, reaching $3.99. 21,103 shares of the stock traded hands, compared to its average volume of 62,531. The stock’s 50-day moving average price is $4.42 and its 200 day moving average price is $3.19. The firm has a market cap of $19.19 million, a price-to-earnings ratio of -0.26 and a beta of 2.46. Senti Biosciences has a fifty-two week low of $1.52 and a fifty-two week high of $16.94.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.